



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: 10/023,636
Applicant: Furman, *et al.*
Filed: December 17, 2001
TC/A.AU.: 1617
Examiner: Russell Travers

Confirmation No. 271

RECEIVED
OCT 10 2003
TECH CENTER 1600/2900

Docket No.: 04674.105068 TRI 1014
Customer No.: 20786
Title: DAPD Combination Therapy with Inosine Monophosphate
Dehydrogenase Inhibitor

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

The citation of information on the attached Form PTO-1449, "List of Art Cited by Applicant" is made pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each cited item is enclosed.

The citation of this information does not constitute an admission of priority or that any cited item is available as a reference, or a waiver of any right the applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.


This Information Disclosure Statement is filed before a final action under § 1.113, but after the mailing date of a first office action on the merits of this application. A check in the amount of \$180 is enclosed to pay the fee set forth under § 1.17(p).

10/09/2003 MROCHA1 00000005 10023636

01 FC:1806

100.00 OP

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on October 3, 2003.


Hoang M. Vo, Reg. No. 47,158

0980. Please charge any additional fees or credit any overpayment to Deposit Account No. 11-

Respectfully submitted,

KING & SPALDING, LLP


By Sherry Knowles *Sherry Knowles*
W/express permission - Modeling Division 36,174

Sherry Knowles

Reg. No. 33,052

Tel.: (404) 572-4600

Enclosures



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	10/023,636
Filing Date	December 17, 2001
First Named Inventor	Furman, <i>et al.</i>
Group Art Unit	1617
Examiner Name	Russell Travers
Attorney Docket Number	04674.105068 TRI 1014

Sheet 1 of 2

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code (if known)			
	AA	2003/0013660	A1	ATTARDO, <i>et al.</i>	01-16-2003	
	AB	5,922,867		MANSOUR, <i>et al.</i>	07-13-1999	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number	Kind Code (if known)				
	AC	WO	00/51641		GU (BioChem Pharma)	09-08-2000	pg 6 ln 13, to pg 12 ln 19.	
	AD	WO	00/51615	A	HEREDIA, <i>et al.</i> , (Univ. Maryland)	09-08-2000	pg 2 ln 27 to pg 3 ln 7; pg 3 ln 22-27; pg 11 ln 12-14; pg 15 ln 3 to pg 16 ln 2	
	AE	WO	01/32153		STORER (IAF Biochem. Int.)	05-10-2001	pg 40, ln 5-17.	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	AF	CORBETT, Amanda H., <i>et al.</i> , <i>Current Opinion in Investigational Drugs</i> , Pharmapress Ltd., 2001, 2 (3), 348-353. XP001097241.	
	AG	FIELD, H.J., <i>et al.</i> , "The 12th International Conference on Antiviral Research", <i>International Antiviral News</i> , Churchill Livingstone, Edinburgh, GB, Vol. 7 no. 3, 1999, pages 34-38. XP000996113.	
	AH	FURMAN, Phillip A., <i>et al.</i> , "DAPD", <i>Drugs of the Future</i> (2000), 25(5), 454-461. XP009004972.	


Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/023,636
				Filing Date	December 17, 2001
				First Named Inventor	Furman, et al.
				Group Art Unit	1617
				Examiner Name	Russell Travers
Sheet	2	of	2	Attorney Docket Number	04676.105049 TRI 1014

RECEIVED
OCT 10 2003
TECH CENTER 1600/2900

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	BA	FURMAN, Phillip A., et al., "Mechanism of Action of 1-beta-D-2,6-diaminopurine dioxolane, a prodrug of the Human Immunodeficiency Virus type I inhibitor 1-beta-d-dioxolane guanosine, <i>Antimicrobial Agents and Chemotherapy</i> (2001), 45(1), 158-165. XP002229309.	
	BB	GU, Z., et al., Mechanism of action and in vitro activity of 1',3'-dioxolanylpurinenucleoside analogues against sensitive and drug-resistant Human Immunodeficiency Virus type I variants, <i>Antimicrobial Agents and Chemotherapy</i> , American Society for Microbiology, Washington, D.C. (US), Vol. 43, no. 10, October 1999, pages 2376-2382, XP00091148.	
	BC	YING, C., et al., Ribavirin and mycophenolic acid potentiate the activity of guanine- and diaminopurine-based nucleoside analogues against hepatitis B virus, <i>Antiviral Research</i> (November 2000), 48 (2), 117-124. XP002229308.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.